Sheaff Brock Investment Advisors’s TG Therapeutics TGTX Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,500	Closed	-$250K	–	584
2021 Q3	$250K	Hold	7,500	–	–	0.02%	426
2021 Q2	$291K	Hold	7,500	–	–	0.02%	373
2021 Q1	$362K	Sell	7,500 -7,500	-50%	-$360K	0.03%	312
2020 Q4	$780K	Hold	15,000	–	–	0.07%	176
2020 Q3	$401K	Hold	15,000	–	–	0.04%	247
2020 Q2	$292K	Hold	15,000	–	–	0.03%	309
2020 Q1	$148K	Hold	15,000	–	–	0.02%	351
2019 Q4	$167K	Hold	15,000	–	–	0.02%	431
2019 Q3	$84K	Hold	15,000	–	–	0.01%	441
2019 Q2	$130K	Hold	15,000	–	–	0.01%	451
2019 Q1	$121K	Hold	15,000	–	–	0.01%	466
2018 Q4	$62K	Hold	15,000	–	–	0.01%	453
2018 Q3	$84K	Buy	+15,000	New	+$171K	0.01%	497

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Sheaff Brock Investment Advisors's TGTX Position: Q4 2021 in Review

Sheaff Brock Investment Advisors sold out of TG Therapeutics (TGTX) in Q4 2021, closing a stake of 7,500 shares — an estimated $250K sold.

Sheaff Brock Investment Advisors first reported a position in TGTX in Q3 2018 and held it in 13 quarters. The position peaked at $780K in Q4 2020. 194 funds tracked by Wall St. Rank hold TGTX as of Q4 2021.

Sheaff Brock Investment Advisors reported no remaining TG Therapeutics position as of Q4 2021 after selling out during the quarter.
Sheaff Brock Investment Advisors sold 7,500 TG Therapeutics shares in Q4 2021, an estimated $250K.
Sheaff Brock Investment Advisors first reported a position in TG Therapeutics in Q3 2018 and held it in 13 quarters.
Sheaff Brock Investment Advisors's TG Therapeutics position peaked at $780K in Q4 2020.
194 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2021.

Based on Sheaff Brock Investment Advisors's 13F filing for Q4 2021, filed 3 Feb 2022.